On October 22, 2024, we acquired privately-held Opus Genetics Inc., a clinical-stage gene therapy company focused on IRDs, in ...

Despite regulation changes in the Chinese healthcare industry, we think CSPC is well-positioned to maintain relatively strong revenue growth. First, generic drugs normally face the most severe price ...

How can you design your own SWAN portfolio? The broader stock market ... that are designed to offer the economic benefit/loss of the covered calls written on the Nasdaq index.

I'll take a minute and highlight here that adjusting on a pro forma basis, the $39.6 million net loss for the $54 million of total non-cash unrealized and realized loan portfolio losses taken in ...

Pulse Biosciences, Inc. (NASDAQ: PLSE) Q4 2024 Earnings Call Transcript March 27, 2025 Pulse Biosciences, Inc. beats earnings ...

India’s equity benchmarks ended nearly flat on Tuesday, pausing after a six-session rally that erased their 2025 losses, as ...

Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth ...

Among individuals and enterprises in India, there seems to be more diligence that dictates regular data backups as an ...

To find the best AI stocks, we look to the Morningstar Global Next Generation Artificial Intelligence Index. The AI stocks on ...

Leatt continued to meet its working capital needs from cash on hand and internally generated cash flow from operations. At December 31, 2024, the Company had cash and cash equivalents of $12.37 ...

further loss of T cell function, both which culminate in recrudescence and disease. Simon, Bugos and colleagues report the design and characterization of monospecific and bispecific synthetic ...